Houston hospital first in U.S. to try experimental plasma treatment

Houston Methodist is the first academic hospital in the country to use a new plasma infusion treatment against COVID-19. Photo by Getty Images

A major Houston hospital is spearheading a crucial treatment in the ongoing battle against COVID-19.

Houston Methodist is the first academic medical center in the nation to be approved by the FDA to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient.

The experimental treatment was fast-tracked as the death toll in the coronavirus pandemic soared to more than 2,000 people across the United States and more than 100,000 Americans sick from the virus, according to a statement.

The concept of the treatment centers around the idea that plasma from someone who has recovered from COVID-19 contains antibodies made by the immune system and used to kill the virus. Transfusing antibody-rich plasma into a COVID-19 patient who is still fighting the virus may transfer the power of the antibodies into a healing, possibly life-saving therapy, per the hospital.

Donating plasma is similar to donating blood and takes about an hour, according to Methodist. Plasma donors are hooked up to a small device that removes plasma while simultaneously returning red blood cells to their bodies. Unlike regular blood donation in which donors have to wait for red blood cells to replenish between donations, plasma can be donated more frequently, as often as twice a week.

Known as convalescent serum therapy, the concept dates back more than a century, when similar treatments were used during the Spanish flu pandemic of 1918, a diphtheria outbreak in the 1920s, a flesh-eating bacteria epidemic in the 1930s, and during other outbreaks of infectious diseases.

Most recently, a description of the treatment of five patients in China was published this week in the Journal of the American Medical Association, suggesting that the treatment was beneficial.

According to Methodist, scientists there recruited blood plasma donors from among approximately 250 patients who have tested positive for the COVID-19 virus at Houston Methodist hospitals. Willing donors were immediately identified; each gave a quart of blood plasma in a procedure much like donating whole blood.

The first recovered COVID-19 patient to donate plasma was an individual from the Houston metropolitan area who has been in good health for more than two weeks, according to the hospital. The plasma was then transfused into a COVID-19 patient at Houston Methodist.

Houston Methodist's convalescent serum therapy treatment is classified as an "emergency investigational new drug protocol" that requires FDA approval for each patient infused with donated convalescent serum, according to the hospital. Houston Methodist physician scientists will continue to seek additional FDA approval for follow-up studies, as time is of the essence.

"Convalescent serum therapy could be a vital treatment route, because unfortunately there is relatively little to offer many patients except supportive care, and the ongoing clinical trials are going to take a while," says Dr. Eric Salazar, principal investigator and a physician scientist in the Department of Pathology and Genomic Medicine at the Houston Methodist Hospital and Research Institute, in a statement. "We don't have that much time."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Data Gumbo, founded and led by Andrew Bruce, has announced its latest funding. Photo courtesy of Data Gumbo

A Houston-based tech company has announced another round of funding to support its blockchain network growth as well as to establish a presence in the Middle East.

Data Gumbo has closed its series B funding round totaling $7.7 million with follow-on investments led by Equinor Ventures. The round includes participation from Saudi Aramco Energy Ventures and Bay Area and Houston-based venture firm L37. The round's first close was announced in September 2020 at $4 million. The additional funds to close the Series B will be used to scale Data Gumbo to serve demand for GumboNetâ„¢ and GumboNetâ„¢ ESG. Additionally, Data Gumbo plans to establish a presence in the Middle East to cover expected demand growth in the region.

"The successful close of our series B is continued proof of the efficacy and booming interest in our ability to capture critical cost savings, deliver trust and provide transparency across commercial relationships," says Andrew Bruce, founder and CEO of Data Gumbo, in a news release. "Compounded by the growing demand for transparent, accurate sustainability data and the launch of our automated ESG measurement solution, GumboNetâ„¢ ESG, Data Gumbo's trajectory is well-positioned to serve our growing customer base by ensuring economic productivity and value. This infusion of capital will support our expansion efforts as we bring more international users to our network."

With this latest raise, Data Gumbo's total funding raised to date is $18.4 million.

"Data Gumbo's success is marked by a wide variety of business use cases and opportunities for expansion," says Bruce Niven, chief investment officer at Aramco Ventures, in the release. "Our continued investment is a testament to our continued support as the company attracts new customers, experiences further demand for its network and gains traction in new markets."

The company's technology features smart contract automation and execution, which reduces contract leakage, frees up working capital, enables real-time cash and financial management, and delivers provenance with unprecedented speed, accuracy, visibility and transparency, per the release.

"Data Gumbo is the market leader for smart contracts backed by blockchain, and the coming year will be a period of exponential growth for the company as they penetrate new industrial markets," says Kemal Farid, partner at L37, in the release. "We believe strongly that GumboNet will become the de facto network for smart contracts across industries for capturing value and solving enormous pain points in contractual relations. Additionally, as companies move to meet increasing sustainability measurement demands and ESG improvements, there is a huge growth path available for Data Gumbo with the launch of GumboNet ESG."

Earlier this year, the company announced its environmental, social and corporate governance tracking and reporting tool.

"Equinor's recent pilot at the Johan Sverdrup field has demonstrated that GumboNet can create strong value for the partnership," says Gareth Burns, head of Equinor Ventures, in the release. "Our follow-on investment confirms Equinor Ventures' confidence in Data Gumbo's solution for our company and the broader energy industry."

Trending News